High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients

著者: Qiao, G-B, Wu, Y-L, Yang, X-N, Zhong, W-Z, Xie, D, Guan, X-Y, Fischer, D, Kolberg, H-C, Kruger, S, Stuerzbecher, H-W
出版事項 2005

Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations

著者: Chen, R.-L., Chen, H.-J., Jiang, B.-Y., Zhang, X.-C., Zhou, Q., Tu, H.-Y., Zhong, W.-Z., Wu, Y.-L., Yang, J.-J.
出版年 Clin Transl Oncol (2017)

Serum C-reactive protein predicts poor prognosis in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy

著者: Zeng, Y.C., Wu, R., Xiao, Y.P., Chi, F., Xue, M., Zhang, Z.Y., Xing, R., Zhong, W.Z., Wang, S.L., Tian, X., Chen, W., Chen, J.J., Wu, L.N.
出版年 Curr Oncol (2015)

A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations

著者: Yang, J J, Zhou, Q, Yan, H H, Zhang, X C, Chen, H J, Tu, H Y, Wang, Z, Xu, C R, Su, J, Wang, B C, Jiang, B Y, Bai, X Y, Zhong, W Z, Yang, X N, Wu, Y L
出版年 Br J Cancer (2017)